- Home
- MHN vs ABSI Comparison
MHN vs ABSI Comparison
Compare MHN & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$3.90
Company Overview
Basic Information| Metric | MHN | ABSI |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.1M | 577.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MHN | ABSI |
|---|---|---|
| Price | $10.28 | $3.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.98 |
| AVG Volume (30 Days) | 59.2K | ★ 3.4M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,815,000.00 |
| Revenue This Year | N/A | $10.72 |
| Revenue Next Year | N/A | $437.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.69 | $2.01 |
| 52 Week High | $10.81 | $6.33 |
Technical Indicators
Market Signals| Indicator | MHN | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 60.88 |
| Support Level | $10.21 | $3.40 |
| Resistance Level | $10.30 | $3.79 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 56.92 | 99.07 |
Price Performance
Historical Comparison MHN
ABSI
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.